Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide Nasal Spray for Lower Airway Inflammation in Children with Allergic Rhinitis
NCT02352168Completed
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Sep 2014
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of EPI-EE in allergic rhinitis (AR) (2 arms), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoints: Fractional exhaled nitric oxide at 3 months and Eosinophils in induced sputum at 3 months. Started Sep 2014; status: completed.
02
Drugs
EPI-EE
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02352168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352168.